UA34419C2 - Ліофілізований препарат для ін'єкцій та спосіб інгібування росту пухлин - Google Patents

Ліофілізований препарат для ін'єкцій та спосіб інгібування росту пухлин

Info

Publication number
UA34419C2
UA34419C2 UA5010680A UA5010680A UA34419C2 UA 34419 C2 UA34419 C2 UA 34419C2 UA 5010680 A UA5010680 A UA 5010680A UA 5010680 A UA5010680 A UA 5010680A UA 34419 C2 UA34419 C2 UA 34419C2
Authority
UA
Ukraine
Prior art keywords
growth inhibition
injectable preparation
tumour growth
lyophilised
lyophilised injectable
Prior art date
Application number
UA5010680A
Other languages
English (en)
Russian (ru)
Inventor
Гаетано Гатті
Гаэтано Гатти
Дієго ОЛДАНІ
Диего Олдани
Карло КОНФАЛОНІЄРІ
Карло Конфалониери
Лучіано Гамбіні
Лучиано Гамбини
Original Assignee
Фармація Енд Апджон С.П.А.
Фармация Энл Апджон С.П.А.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Фармація Енд Апджон С.П.А., Фармация Энл Апджон С.П.А. filed Critical Фармація Енд Апджон С.П.А.
Publication of UA34419C2 publication Critical patent/UA34419C2/uk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Даний винахід стосується стабільних, швидкорозчинних, ліофілізованих, придатних для ін’єкцій препаратів, що містять глікозид антрацикліну або його фармацевтично прийнятну сіль як активного лікарського засобу, а також застосування вказаних препаратів для лікування пухлин.
UA5010680A 1984-10-22 1985-10-18 Ліофілізований препарат для ін'єкцій та спосіб інгібування росту пухлин UA34419C2 (uk)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB848426672A GB8426672D0 (en) 1984-10-22 1984-10-22 Pharmaceutical compositions

Publications (1)

Publication Number Publication Date
UA34419C2 true UA34419C2 (uk) 2001-03-15

Family

ID=10568553

Family Applications (2)

Application Number Title Priority Date Filing Date
UA5010680A UA34419C2 (uk) 1984-10-22 1985-10-18 Ліофілізований препарат для ін'єкцій та спосіб інгібування росту пухлин
UA3964940A UA19169A (uk) 1984-10-22 1985-10-18 Спосіб одержаhhя порошку ліофілізоваhого аhтрацикліh глікозиду

Family Applications After (1)

Application Number Title Priority Date Filing Date
UA3964940A UA19169A (uk) 1984-10-22 1985-10-18 Спосіб одержаhhя порошку ліофілізоваhого аhтрацикліh глікозиду

Country Status (35)

Country Link
US (4) US4675311A (uk)
JP (1) JPH0611700B2 (uk)
KR (1) KR920005813B1 (uk)
CN (1) CN85107562B (uk)
AT (1) AT401345B (uk)
AU (1) AU572003B2 (uk)
BE (1) BE903484A (uk)
BG (1) BG60934B2 (uk)
CA (1) CA1248453A (uk)
CH (1) CH667594A5 (uk)
CS (1) CS270421B2 (uk)
DE (1) DE3536896C2 (uk)
DK (1) DK165620C (uk)
ES (1) ES8605374A1 (uk)
FI (2) FI853913A7 (uk)
FR (1) FR2571966B1 (uk)
GB (2) GB8426672D0 (uk)
GR (1) GR852549B (uk)
HK (1) HK94390A (uk)
HU (1) HU197988B (uk)
IE (1) IE56992B1 (uk)
IL (1) IL76732A (uk)
IT (1) IT1186779B (uk)
MY (1) MY103956A (uk)
NL (1) NL191308C (uk)
NO (1) NO170616C (uk)
NZ (1) NZ213885A (uk)
PH (1) PH23982A (uk)
PT (1) PT81347B (uk)
RU (2) RU1836088C (uk)
SE (1) SE467520B (uk)
SG (1) SG80290G (uk)
UA (2) UA34419C2 (uk)
YU (1) YU46160B (uk)
ZA (1) ZA858033B (uk)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5124317A (en) 1985-08-02 1992-06-23 Farmitalia Carlo Erba S.P.A. Injectable ready-to-use solutions containing an antitumor anthracycline glycoside
US5124318A (en) * 1985-08-02 1992-06-23 Farmitalia Carlo Erba S.R.L. Injectable ready-to-use solutions containing an antitumor anthracycline glycoside
US5977082A (en) 1985-08-02 1999-11-02 Pharmacia & Upjohn Company Injectable ready-to-use solutions containing an antitumor anthracycline glycoside
NO175802C (no) * 1986-12-05 1994-12-14 Erba Farmitalia Fremgangsmåte for fremstilling av en lagringsstabil antracyklinglycosidopplösning
JP2603480B2 (ja) * 1987-08-05 1997-04-23 住友製薬株式会社 安定化されたアンスラサイクリン系製剤
DE3801178A1 (de) * 1988-01-18 1989-07-27 Hoechst Ag Stabilisierte trockenzubereitung zytostatisch wirksamer anthracyclin-antibiotika und verfahren zu ihrer herstellung
US6300361B1 (en) 1990-07-25 2001-10-09 Novartis Ag Stabilized pharmaceutical compositions comprising acid donors
AU741439B2 (en) 1996-12-30 2001-11-29 Battelle Memorial Institute Formulation and method for treating neoplasms by inhalation
US5942508A (en) * 1997-02-04 1999-08-24 Senju Pharmaceutical Co., Ltd. Method for solubilizing pyridonecarboxylic acid solubilizer thereof and aqueous solution containing solubilized pyridonecarboxylic acid
RU2292216C2 (ru) * 2000-10-31 2007-01-27 Фарма Мар, С.А. Кахалалид f
CN101172104B (zh) 2002-02-22 2013-04-03 默沙东公司 抗肿瘤剂,特别是替莫唑胺的药物制剂,其制备方法和用途
EP1474995B1 (en) * 2003-05-06 2012-11-14 Gumlink A/S A method for producing chewing gum granules, a gum composition extruder and granulating system, and a chewing gum product
CN100412084C (zh) * 2003-07-02 2008-08-20 獀洛克斯股份有限公司 热稳定的结晶盐酸表柔比星及其制造方法
US20090099346A1 (en) * 2003-07-02 2009-04-16 Victor Matvienko Thermally stable crystalline epirubicin hydrochloride
ES2425083T3 (es) * 2003-09-25 2013-10-11 Astellas Pharma Inc. Agente antitumoral que comprende FK228 como inhibidor de histona desacetilasa y doxorrubicina como inhibidor de topoisomerasa II
RU2262923C2 (ru) * 2003-12-25 2005-10-27 Государственное образовательное учреждение высшего профессионального образования Курский государственный медицинский университет Министерства здравоохранения Российской Федерации Иммобилизованная форма доксорубицина
US7388083B2 (en) * 2005-03-07 2008-06-17 Solux Corporation Epimerization of 4′-C bond and modification of 14-CH3-(CO)-fragment in anthracyclin antibiotics
BRPI0605832A2 (pt) * 2005-05-11 2009-05-26 Sicor Inc glicosìdeos de antraciclina liofilizados estáveis
CA2615173C (en) 2005-07-14 2012-01-03 Lipothera, Inc. Sustained release enhanced lipolytic formulation for regional adipose tissue treatment
RU2450013C2 (ru) * 2005-12-13 2012-05-10 Солюкс Корпорейшен Способ получения 4-деметилдаунорубицина
US8802830B2 (en) * 2005-12-20 2014-08-12 Solux Corporation Synthesis of epirubicin from 13-dihydrodaunorubicine
US8148338B2 (en) * 2006-02-22 2012-04-03 Supratek Pharma Inc. Doxorubicin formulations for anti-cancer use
US7470672B2 (en) * 2006-07-31 2008-12-30 Savvipharm Inc. Compositions and methods of reducing tissue levels of drugs when given as orotate derivatives
CN101743020A (zh) * 2007-05-16 2010-06-16 Ktb肿瘤研究有限责任公司 低粘度蒽环制剂
EP2184066B1 (en) * 2007-09-04 2013-11-06 Meiji Seika Pharma Co., Ltd. Injection, injection solution and injection kit preparation
KR20100058662A (ko) * 2007-10-26 2010-06-03 화이자 프로덕츠 인코포레이티드 개에게서 림프종을 치료하기 위한 이다루비신
US8357785B2 (en) * 2008-01-08 2013-01-22 Solux Corporation Method of aralkylation of 4′-hydroxyl group of anthracylins
US9132084B2 (en) 2009-05-27 2015-09-15 Neothetics, Inc. Methods for administration and formulations for the treatment of regional adipose tissue
GB2487868B (en) * 2010-01-15 2014-12-10 Neothetics Inc Lyophilized cake formulations
UA111822C2 (uk) 2010-11-24 2016-06-24 Общєство С Огранічєнной Отвєтствєнностью "Новамедіка" Монотерапевтичий препарат селективного ліпофільного бета-агоніста тривалої дії і спосіб косметичного лікування ожиріння і контурного випинання
DE102011103751A1 (de) 2011-05-31 2012-12-06 Heraeus Precious Metals Gmbh & Co. Kg Kristallisierung von Epirubicinhydrochlorid
DE102011111991A1 (de) * 2011-08-30 2013-02-28 Lead Discovery Center Gmbh Neue Cyclosporin-Derivate
CA2894548C (en) 2012-12-13 2021-01-12 Cytrx Corporation Anthracycline formulations
CN113842392A (zh) 2013-06-05 2021-12-28 西特克斯公司 用于治疗癌症的细胞毒素剂

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
YU33730B (en) * 1967-04-18 1978-02-28 Farmaceutici Italia Process for preparing a novel antibiotic substance and salts thereof
US4039663A (en) * 1975-03-19 1977-08-02 Societa' Farmaceutici Italia S.P.A. Daunomycins, process for their uses and intermediates
GB1506200A (en) * 1975-04-30 1978-04-05 Farmaceutici Italia Glycosides
GB1567456A (en) * 1976-11-16 1980-05-14 Farmaceutici Italia Daunomycin derivatives
US4177264A (en) * 1977-10-17 1979-12-04 Sri International N-benzyl anthracyclines
GB2007645B (en) * 1977-10-17 1982-05-12 Stanford Res Inst Int Benzyl anthracyclines and pharmaceutical compositions containing them
JPS563851A (en) * 1979-06-22 1981-01-16 Matsushita Electric Works Ltd Fireplace in floor
JPS5756494A (en) * 1980-09-22 1982-04-05 Microbial Chem Res Found New anthracyclin derivative
US4325947A (en) * 1981-05-12 1982-04-20 Farmitalia Carlo Erba S.P.A. 4-Demethoxy-4'-deoxydoxorubicin
IT1210476B (it) * 1981-05-28 1989-09-14 Erba Farmitalia Antracicline.
US4438105A (en) * 1982-04-19 1984-03-20 Farmaitalia Carlo Erba S.P.A 4'-Iododerivatives of anthracycline glycosides
AT380480B (de) * 1982-05-24 1986-05-26 Erba Farmitalia Verfahren zur herstellung von anthracyclinglykosiden
US4464529A (en) * 1982-07-20 1984-08-07 Sri International Analogues of morpholinyl daunorubicin and morpholinyl doxorubicin
CA1248944A (en) * 1982-09-28 1989-01-17 Gareth J. Thomas Anthracycline glycosides
JPS5982395A (ja) * 1982-11-02 1984-05-12 Microbial Chem Res Found アントラサイクリン化合物、その製造法およびその用途
GR79729B (uk) * 1982-12-20 1984-10-31 Univ Ohio State Res Found
JPS6092212A (ja) * 1983-10-26 1985-05-23 Kyowa Hakko Kogyo Co Ltd ドキソルビシン塩の製剤
US4537882A (en) * 1984-05-10 1985-08-27 Ohio State University 4-Demethoxy-3'-desamino-2'-halo-anthracycline and pharmaceutical composition containing same

Also Published As

Publication number Publication date
NO854194L (no) 1986-04-23
AT401345B (de) 1996-08-26
GB2165751A (en) 1986-04-23
RU1836088C (ru) 1993-08-23
DE3536896A1 (de) 1986-04-24
JPS61246129A (ja) 1986-11-01
DK165620C (da) 1993-06-01
DK481585D0 (da) 1985-10-21
DE3536896C2 (de) 1996-11-14
IL76732A (en) 1989-07-31
IL76732A0 (en) 1986-02-28
NL191308B (nl) 1994-12-16
AU4880585A (en) 1986-05-01
NO170616C (no) 1992-11-11
IE56992B1 (en) 1992-02-26
MY103956A (en) 1993-10-30
GB8426672D0 (en) 1984-11-28
YU46160B (sh) 1993-05-28
BG60934B2 (bg) 1996-06-28
RU2101018C1 (ru) 1998-01-10
GB2165751B (en) 1988-08-17
CS756585A2 (en) 1989-11-14
SE8504945D0 (sv) 1985-10-21
CH667594A5 (de) 1988-10-31
SE467520B (sv) 1992-08-03
US5091373A (en) 1992-02-25
FR2571966A1 (fr) 1986-04-25
CN85107562A (zh) 1986-07-23
HU197988B (en) 1989-07-28
DK165620B (da) 1992-12-28
SE8504945L (sv) 1986-04-23
ES547578A0 (es) 1986-03-16
PT81347A (en) 1985-11-01
NZ213885A (en) 1988-05-30
HUT40759A (en) 1987-02-27
FI86252B (fi) 1992-04-30
GB8525709D0 (en) 1985-11-20
YU164485A (en) 1987-10-31
UA19169A (uk) 1997-12-25
GR852549B (uk) 1986-02-24
IE852593L (en) 1986-04-22
CN85107562B (zh) 1988-06-01
DK481585A (da) 1986-04-23
ES8605374A1 (es) 1986-03-16
PT81347B (pt) 1987-11-11
FI854035L (fi) 1986-04-23
FR2571966B1 (fr) 1988-04-15
IT8522507A0 (it) 1985-10-16
US4675311A (en) 1987-06-23
BE903484A (fr) 1986-04-21
PH23982A (en) 1990-02-09
FI853913A7 (fi) 1986-04-23
JPH0611700B2 (ja) 1994-02-16
NL8502869A (nl) 1986-05-16
NL191308C (nl) 1995-05-16
US4840938A (en) 1989-06-20
HK94390A (en) 1990-11-23
ZA858033B (en) 1986-06-25
US5091372A (en) 1992-02-25
AU572003B2 (en) 1988-04-28
KR860003014A (ko) 1986-05-19
IT1186779B (it) 1987-12-16
ATA303285A (de) 1996-01-15
KR920005813B1 (ko) 1992-07-20
FI854035A0 (fi) 1985-10-16
FI86252C (fi) 1992-08-10
CS270421B2 (en) 1990-06-13
CA1248453A (en) 1989-01-10
NO170616B (no) 1992-08-03
FI853913A0 (fi) 1985-10-08
SG80290G (en) 1990-11-23

Similar Documents

Publication Publication Date Title
UA34419C2 (uk) Ліофілізований препарат для ін'єкцій та спосіб інгібування росту пухлин
EP0395329A3 (en) composition in the form of a foam containing 5-aminosalicylic acid for intra-rectal administration
HUT58511A (en) Process for producing pharmaceutical compositions comprising toremifen and its metabolites, suitable for ceasing the simultaneous resistance of cancer cells to several cytotoxic active ingredients
AU576365B2 (en) Collagen and or fibrinogen as carrier of drugs for their introduction into cellular lesion areas
AU2789989A (en) Acylated uridine and cytidine and uses thereof
CA2291065A1 (en) Raf kinase inhibitors
CA2068324A1 (en) Metal-peptide compositions and methods for stimulating hair growth
HU9302496D0 (en) Method for producing anti-viral nucleoside combinations and one for preparing medical preparatives containing said compounds
BG103647A (en) Cisplatina containing microgranules
HU9201937D0 (en) Aryl ethers, process for their production, and for the production of medical preparations containing them as active agents
MY109309A (en) Improvements in or relating to somatostatins
MY102549A (en) Crystalline calcium pseudomonate and a process for preparing the same and its use as a pharmaceutical composition
ES8800601A1 (es) Un procedimiento para preparar una formulacion farmaceutica liofilizada de activador de plasminogeno de tejidro (t-pa)
CA2209315A1 (en) Gibberellins compounds for veterinary and medicinal applications
EP0137543A3 (en) Pharmaceutical composition for the therapy of peripheral arteriopathies
HU9300624D0 (en) Medical preparatives for treating hard tumours containing il-4 as active substance and method for produicng them
GB1395090A (en) Stabilized hormone compositions
EP0281070A3 (en) Pharmaceutical composition for the treatment of cancer
AU7999787A (en) Active compounds for use in the treatment of tumors
ES8703742A1 (es) Procedimiento para preparar un agente acuoso esteril de ac- cion retardada y prolongada,de un peptido o de una proteina
FI871545A7 (fi) Menetelmä syövän hoitoon käytettävän synergistisen seoksen valmistamiseksi, joka sisältää interleukiini-2:ta ja/tai interferoni- :aa ja kasvainnekroositekijää.
GB1474424A (en) Pharmaceutical composition for treating diabetic ketoacidosis
CA2283739A1 (en) Ascorbic acid as an adjuvant in treatment of malignant tumors by chemotherapy and radiotherapy
ES8801624A1 (es) Procedimiento para preparar disulfuros heterociclicos
MD457G2 (ro) Derivaţi noi de naftiridină, procedeu de preparare a lor, compoziţii farmaceutice care le conţin, utilizarea lor ca medicamente de antireproducere